PTCT (STOCKS)
PTC Therapeutics, Inc.
$70.420000
+1.730000 (+2.52%)
Prev close: $68.690000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Matthew B. Klein
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $5,826.51M
- Employees
- 939
- P/E (TTM)
- 8.83
- P/B (TTM)
- -27.94
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $1.73B |
| Benefits Costs and Expenses | $1.03B |
| Costs And Expenses | $1.03B |
| Operating Expenses | $863.72M |
| Selling, General, and Administrative Expenses | $347.14M |
| Research and Development | $455.25M |
| Other Operating Expenses | $61.33M |
| Operating Income/Loss | $866.94M |
| Income/Loss From Continuing Operations After Tax | $682.64M |
| Income/Loss From Continuing Operations Before Tax | $696.62M |
| Income Tax Expense/Benefit | $13.98M |
| Income Tax Expense/Benefit, Deferred | -$3.00K |
| Net Income/Loss | $682.64M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $682.64M |
| Net Income/Loss Available To Common Stockholders, Basic | $682.64M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $8.58 |
| Diluted Earnings Per Share | $7.78 |
| Basic Average Shares | 79,534,290 |
| Diluted Average Shares | 88,311,494 |
| Assets | $2.90B |
| Current Assets | $2.27B |
| Accounts Receivable | $181.62M |
| Inventory | $79.65M |
| Other Current Assets | $2.01B |
| Noncurrent Assets | $624.82M |
| Fixed Assets | $55.37M |
| Intangible Assets | $388.75M |
| Other Non-current Assets | $180.70M |
| Liabilities | $3.10B |
| Current Liabilities | $968.43M |
| Accounts Payable | $45.49M |
| Wages | $73.74M |
| Other Current Liabilities | $849.20M |
| Noncurrent Liabilities | $2.14B |
| Equity | -$205.31M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$205.31M |
| Liabilities And Equity | $2.90B |
| Net Cash Flow From Operating Activities | $711.20M |
| Net Cash Flow From Operating Activities, Continuing | $711.20M |
| Net Cash Flow From Investing Activities | -$861.98M |
| Net Cash Flow From Investing Activities, Continuing | -$861.98M |
| Net Cash Flow From Financing Activities | $331.09M |
| Net Cash Flow From Financing Activities, Continuing | $331.09M |
| Net Cash Flow | $180.31M |
| Net Cash Flow, Continuing | $180.31M |
| Comprehensive Income/Loss | $719.03M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $719.03M |
| Other Comprehensive Income/Loss | $719.03M |
| Other Comprehensive Income/Loss Attributable To Parent | $36.39M |